Recap: Adaptimmune Therapeutics Q1 Earnings


Adaptimmune Therapeutics ADAP reported its Q1 earnings results on Friday, May 12, 2023 at 07:30 AM.

Here's what investors need to know about the announcement.


Adaptimmune Therapeutics missed estimated earnings by 100.0%, reporting an EPS of $0.0 versus an estimate of $-0.14.

Revenue was up $44.03 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.07 which was followed by a 5.3% drop in the share price the next day.

Here's a look at Adaptimmune Therapeutics's past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.25 -0.24 -0.25 -0.22
EPS Actual -0.18 -0.24 -0.28 -0.32
Revenue Estimate 4.12M 4.04M 6.00M 3.29M
Revenue Actual 11.03M 7.01M 5.54M 3.58M

To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!